Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.

Autor: Conticello C; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. ettaconticello@gmail.com., Romano A; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. sandrina.romano@gmail.com., Del Fabro V; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. vdelfabro@yahoo.it., Martino EA; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. enricaantoniamartino@libero.it., Calafiore V; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. valeriacalaf@gmail.com., Sapienza G; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. sapienzagius@gmail.com., Leotta V; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. valerio_leotta@yahoo.it., Parisi MS; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. marinaparisi@hotmail.it., Markovic U; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. urosmarkovic09041989@gmail.com., Garibaldi B; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. brunga93@gmail.com., Leotta S; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. leotta3@yahoo.it., Cotzia E; U.O.C. Ematologia, ASP8, 96100 Siracusa, Italy. cotemi@hotmail.it., Innao V; Division of Hematology, Dipartimento di Patologia Umana dell'Adulto e dell'Età Evolutiva, Policlinico G. Martino, University of Messina, 98122 Messina, Italy. vinnao@unime.it., Mannina D; U.O.C. Ematologia, Azienda Ospedaliera Papardo, 98158 Messina, Italy. donamanni@gmail.com., Neri S; U.O.C. Ematologia, Azienda Ospedaliera Papardo, 98158 Messina, Italy. santoneri67@gmail.com., Musso M; U.O.C. OncoEmatologia e TMO, Dipartimento Oncologico, La Maddalena, 90146 Palermo, Italy. mamusso53@gmail.com., Scalone R; U.O.C. OncoEmatologia e TMO, Dipartimento Oncologico, La Maddalena, 90146 Palermo, Italy. r.scalone69@gmail.com., Cangialosi C; U.O.C. Ematologia A. O. Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy. clotildecangialosi@gmail.com., Acquaviva F; U.O.C. Ematologia A. O. Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy. clotildecangialosi@hotmail.com., Cardinale G; U.O.C. Ematologia, ARNAS-Civico-Di Cristina-Benfratelli, 90147 Palermo, Italy. cardinaleg@libero.it., Merenda A; U.O.C. Ematologia, ARNAS-Civico-Di Cristina-Benfratelli, 90147 Palermo, Italy. anxur.merenda@arnascivico.it., Maugeri C; Division of Hematology, Sant'Elia Hospital, 93100 Caltanissetta, Italy. maugericinzia@hotmail.com., Uccello G; U.O.C. Ematologia, ARNAS Garibaldi, 95122 Catania, Italy. giusy83@virgilio.it., Poidomani M; SIMT Hematology, ASP7, 97100 Ragusa, Italy. massimo.poidomani@asp.rg.it., Longo G; U.O.C. Ematologia, Ospedale San Vincenzo, 98039 Taormina (ME), Italy. longo_giuseppe@hotmail.com., Carlisi M; U.O.C. Ematologia, Policlinico P. Giaccone, 90127 Palermo, Italy. melania.carlisi@unipa.it., Tibullo D; Department of Biomedical and Biotechnological Science, University of Catania, 95125 Catania, Italy. d.tibullo@unict.it., Di Raimondo F; Division of Hematology, Azienda Policlinico-OVE, University of Catania, 95125 Catania, Italy. diraimon@unict.it.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2019 Jun 19; Vol. 8 (6). Date of Electronic Publication: 2019 Jun 19.
DOI: 10.3390/jcm8060877
Abstrakt: Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we report real life results of KRd given to 130 RRMM patients from 12 Sicilian Centers. Results: Median age was 62 years; patients had received a median of two previous lines of treatment (range 1-10) and 52% were refractory to previous treatment. Median number of KRd cycles was 12 (2-29), with a mean duration of treatment of 12 months; 21 patients had received at least 18 cycles. Overall response rate was 61%, including 18% complete response. Median PFS was 22.9 months, median OS was not reached. Creatinine clearance >30 mL/min, quality of the best achieved response and standard Fluorescence In Situ Hybridization (FISH) risk were independent predictors of favorable outcome. Patients who received the full-dosage of carfilzomib in the first two cycles had a better outcome. Conclusions: KRd was effective and well tolerated and in a considerable proportion of patients, therapy continued beyond the 18th cycle. The finding of a better outcome in patients with the higher cumulative dose of carfilzomib in the first two cycle encourages to maintain the maximum tolerated dose.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje